March 29, 2023
Kristin Stafford Joins Novocure Board of Directors
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “Her broad expertise in finance in the life sciences sector and experience… Read More
learn more
March 16, 2023
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields) as well as to encourage… Read More
learn more
March 1, 2023
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
Optune is now available as a treatment for newly diagnosed glioblastoma patients in France ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering… Read More
learn more
March 1, 2023
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Final data from the METIS study anticipated in 2024 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with… Read More
learn more
